

---

**REFERENCES**

1. Goyal RK, Mehta AA, Balaraman R, Burande MD. *Elements of pharmacology*. 14<sup>th</sup> ed. Ahmedabad: B.S. Shah prakashan; 2004. p.529.
2. Sharma HL, Sharma KK. *Principles of pharmacology*. 1<sup>st</sup> ed. Hyderabad: Paras Medical Publisher; 2008. p. 788-89.
3. Rang HP, Dale MM, Ritter JM, Moore PK. *Pharmacology*. 5<sup>th</sup> ed. New Delhi: Elsevier, a division of reed Elservier India Pvt. Ltd.; 2006. p. 666.
4. Roderick J. Hay RJ. Fungal infections. *Clin Dermato* 2006; 24: 201-12.
5. *British Pharmacopoeia*. 1993; Vol-II, A-157.
6. Vidyasagar G. *Pharmabuzz* 2007; 2(7): 31-42.
7. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants. Geneva, *World Health Organization*; 2003. p. 4.
8. Chauhan VS. *The Pharma Review*. 2006; 1: 37-44.
9. Pandey NN, Agrawal P. *Sachitra Ayurveda*. 2000; 05: 369.
10. WHO Quality Control methods for medicinal plant materials. Geneva, *World Health Organization*; 1998. p. 1-15.
11. Vinod Rangari. *Pharmacognosy and Phytochemisrty*. 5<sup>th</sup> ed. 2005; Vol.-I, p. 86-102.
12. Khandelwal KR, Pawar AP, Kokate CK, Gokhle SB. *Practical Pharmacognosy*. 1995. p. 141.
13. Purohit AP, Kokate CK, Gokhle SB. *Pharmacognosy*. 1999. p. 74.
14. Surver, C, Davis FA. *Bioavailability and bioequivalence*. In: Walter KA. Dermatological and transdermal formulation. New York: Marcal Dekker Inc; 2002. p. 323-403.

15. Mishra B, Kumar P, Shankar C. Delivery of macromolecules through skin. *The Indian Pharmacist* 2004; 3(24): 7-16.
16. Jain NK. *Controlled and novel drug delivery*. 1<sup>st</sup> ed. Delhi: CBS Publishers and Distributors; 1997. p. 100-06.
17. Storm JE, Collier SW, Stewart S. Metabolism of xenobiotics during percutaneous penetration: Role of absorption rate and cutaneous enzyme activity. *Fundam Appl Toxicol* 1990; 132-41.
18. Banker GS, Chalmers RK. *Pharmaceutics and pharmacy practice*. 1<sup>st</sup> ed, New York: Lippincott Company; 1982. p. 288-294.
19. Williams A. *Transdermal and topical drug delivery*. Pharmaceutical press, New York, 2003; 2-56.
20. Potts RO, Buras EM, Chrisman DA. Changes with age in moisture content of human skin. *J Invest Dermatol* 1984; 82: 97-100.
21. Roskos VK, Maibach HI. The effect of aging on percutaneous absorption in man. *J Pharmaco Biopharm* 1989; 17: 617-30.
22. Fenske NA, Lober CW. Structural and functional changes of normal ageing skin. *J American Academy Dermatol* 2003; 48: 517-85.
23. Ancel HC. *Introduction to Pharmaceutical dosage forms*. 4<sup>th</sup> ed. Philadelphia: Lea & Feiger; 1985. p. 291-320.
24. Winfield AJ, Richards RME. *External Preparations*. 3<sup>rd</sup> ed. New York: Churchill Livingstone; 2004. p. 206-17.
25. Berardesca E, Maibach HI. Racial differences in pharmacodynamic response to nicotines in vivo in human skin: black and white. *Acta Dermato-Venereologica* 1990; 70: 63-6.

26. Wester RC, Maibach HI. *Regional variations in percutaneous absorption*. In: Bronaugh RL, Maibach HI. *Percutaneous absorption*. 2<sup>nd</sup> ed. New York: Marcel Dekker; 1989. p. 111-20.
27. Barry BW. *Transdermal drug delivery*. In: Aulton ME, *Pharmaceutics, The science of dosage form design*, 2<sup>nd</sup> ed. Edinburgh: Churchill Livingstone; 2002. p.499-532.
28. Southwell D, Barry BW, Variation in permeability of human skin within and between specimens. *Int J Pharm* 1984; 18: 299-309.
29. Benfeldt E, Serup J, Menne T. Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin: In vivo pharmacokinetics using microdialysis and non-invasive quantitation of barrier function. *British J Dermato* 1999; 140: 739-48.
30. Mills PC, Cross SE. *Transdermal drug delivery: Basic principles for the veterinarian*. *The Veterinary J* 2006; 172: 218-33.
31. Kaplun-Frischoff Y, Touitou E. Testosterone skin permeation enhancement by L-Methanol through formation of eutectic with drug and interaction with skin lipids. *J Pharma Sci* 1997; 86: 1394-99.
32. Moss GP, Dearden JC, Patel H, Cronin MD. Quantitative structure-permeability relationships (QSPRs) for percutaneous absorption. *Toxicology In Vitro* 2000; 16: 299-317.
33. Magnusson BM, Pugh WJ, Roberts MS. Simple rules defining the potential of compounds for transdermal delivery or toxicity. *Pharma research* 2004; 21: 1047-54.
34. Magnusson BM, Anissomov YG, Cross SE, Roberts MS. Molecular size as the main determinant of solute maximum flux across the skin. *J Invest Dermato* 2004; 122: 993-99.

- 
35. Ansel HC, Allen LV. *Pharmaceutical dosage forms and drug delivery system*. 7<sup>th</sup> ed. Baltimore: Lippincott Williams and Wilkens; 2000. p. 244-65.
36. Banker GS, Rodes CT. *Modern Pharmacist*. 2<sup>nd</sup> ed. Vol. 40, New York: Marcel Dekker Inc; 1979. p. 263-311.
37. Lachman L, Lieberman HA, Kanig JC. *The theory and practice of industrial pharmacy*. 3<sup>rd</sup> ed. Bombay: Varghese Publishing House; 1991. p. 479-618.
38. Zatz JL, Kushala GP. Gels. In: Liberman HA, Rieger MM, Banker GS. *Pharmaceutical dosage forms: Dispersed systems*. 2<sup>nd</sup> ed. Vol II. London: Informa healthcare; 2008. p. 399-418.
39. Vyas, S. P. and Khar, Roop K., *Controlled Drug Delivery*, 1<sup>st</sup> ed. Delhi: Vallabh Prakashan, 2002. p. 416-17.
40. Flynn GL. *Cutaneous and transdermal delivery- Processes and systems of delivery*. In: Banker GS, Rodes CT. *Modern Pharmaceutics*. 4<sup>th</sup> ed. Revised and Expanded, New York: Marcel Dekker Inc; 2007. p. 215-16.
41. Sanmathi BS, Mehta KK, Patel J, Patel M. *Practical hand book of pharmaceutics*. Ahmedabad: Books India Publication; 2007. p. 351-52.
42. *Indian Herbal Pharmacopoeia*. Revised new ed. Mumbai: Indian drug manufacturers association; 2002. p. 206-13.
43. E:\embelin p f\Embelia Ribes, Bidang, Vayavidnag Herb, Benefits, Information.mht
44. Sharma PC, Yelne MB, Dennis TJ. *Database on medicinal plants used in ayurveda*. Vol V; 2002. p. 478-99.
45. Anonymous, Quality standards of Indian medicinal plants. Vol IV. *Indian Council of Medicinal Research*; 2006. p. 130-36.
46. E:\embelin p f\shopcontent.mht

- 
47. Williamson ME. *Major herbs of ayurveda*. Dabar Research Foundation and Dabar Ayurveda Limited; 2002: 129-34.
  48. Goodrich BF. *Bulletin: Sustained release patents using carbopol resin*. B F Goodrich Company, 1987: 576-98.
  49. Carnali JO, Naser MS. The use of dilute solution viscosity to characterize the network properties of carbopol® microgels. *Colloid & Polymer Sci* 1992; 270(2): 183-93.
  50. Garcia-Gonzalez N, Kellaway IWB, Fuente HA, Igea SD, Charro BO, Espinar FJ, Mendez J. "Influence of glycerol concentration and carbopol molecular weight on swelling and drug release characteristics of metoclopramide hydrogels. *Int J Pharm* 1994; 104: 107-13.
  51. Jani FP. Novel oral-drug formulations-their potential in modulating adverse-effects. *Drug Saf* 1994; 410(3): 233-66.
  52. Rowe RC, Sheskey PJ, Owen SC. *Pharmaceutical excipients*. 5<sup>th</sup> ed. London: Pharmaceutical press; 2003.
  53. Reynolds JEF. *Martindale-The complete drug reference*, 33<sup>rd</sup> ed. London: Pharmaceutical Press; 2002. 1499.
  54. Washington DC. *Handbook of pharmaceutical excipients*. American Pharmaceutical Association / Pharmaceutical Society of Great Britain; 1986. p. 41-42.
  55. Meyer RJ, Cohen L. The rheology of natural and synthetic hydrophilic polymer solutions as related to suspending ability. *J Soc Cosmetic Chemists* 1958; 12: 200-12.
  56. Reloar LRG. *The physics of rubber elasticity*. Oxford University Press, New York, 1958. 469-83.

- 
57. Peppas NA. Characterization of cross-linked structure of hydrogels. *Med Pharm* 1986; 1: 27-56.
58. Brannon-Peppas L. Preparation and characterization of cross-linked hydrophilic networks. *Poly Sci* 1990; 8: 45-66.
59. Hooper HH, et al. Swelling equilibrium for positively ionized poly (acrylamide) hydrogels. *Macromol* 1990; 23(4): 1096-1104.
60. Nae HN, Reichert WW. Rheological properties of lightly cross-linked carboxy copolymers in aqueous solutions. *Rheolo Acta* 1992; 31 (4): 351-60.
61. Ishikawa S. Evaluation of the rheological properties of various kinds of carboxyvinyl polymer gels. *Chem Pharm Bull* 1988; 36(6): 2118-27.
62. Durrani MJ, Whitaker R, Benner SC. A comparative study of controlled release agents- I: Effects of compression force and polymer concentration. *Am Asso Pharm Sci* 1992; 7: 167-71.
63. Perez-Marcos B, Gutierrez C, Gomez-Amoza JL, Martinez-Pacheco R, Souto C, Concheiro A. Usefulness of certain varieties of carbomer in the formulation of hydrophilic furosemide matrices. *Int J Pharm* 1991; 67(2):113-21.
64. Perez-Marcos, B, Iglesias R, Gomez-Amoxa JL. Mechanical and drug release properties of atenolol-carbomer hydrophilic matrix tablets. *J Control Release* 1991; 17(3): 267-76.
65. Guo JH. Investigating the bioadhesive properties of polymer patches for buccal drug delivery (Carbopol 934P). *J Control Release* 1994; 28(1): 272-73.
66. Guo JH. Bioadhesive polymer buccal patches for buprenorphine controlled delivery formulation: In vitro adhesion and release properties. *Drug Del Ind Pharm* 1994; 20(18): 2809-21.

67. Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery- I: Viscous solutions. *Pharm Res* 1991; 8(8): 1039-43.
68. Davies NM, Farr SJ, Hadgraft J, Kellaway IW. Evaluation of mucoadhesive polymers in ocular drug delivery- II: Polymer-coated vesicles. *Pharm Res* 1992; 9(9): 1137-44.
69. Akiyama Y, Nagahara N, Hirai S, Toguchi H. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly (acrylic acid) derivative. *Pharm Res* 1995; 12(3): 397-405.
70. Micheal IU, Exaud S, Guy VDM, Norbert V, Renaat K. Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: Influence of drug loading on in vitro and in vivo release in rabbits. *Int J Pharm* 1999; 181: 125-38.
71. Claudia V, Constantia EK, Irene H, Andreas B. Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone. *J Control Release* 2001; 77: 323-32.
72. ElHady SSA, Mortada ND, Awad GAS, Zaki NM, Taha RA. Development of in situ gelling and mucoadhesive gel of mebeverine hydrochloride. *Saudi Pharm J* 2003; 1(4): 59-169.
73. Al-Khamis KI, Davis SS, Hadcraft J. Microviscosity and drug release from topical gel formulations. *Pharma Res* 1986; 3(4): 214-17.
74. Briede RH. Application of carbomer water gel 1%. *Pharm Week* 1983; 118(9): 170-74.
75. Berney BM, Deasy PB. Evaluation of carbopol 934P as a suspending agent for sulfadimidine suspensions. *Int J Pharm* 1979; 3(2-3): 73-80.

- 
76. Gumma A. Measurability of the bioavailability of an active principle applied topically. *Pharm Acta* 1971; 46(12): 7306.
77. Machida Y, Masuda H, Fujiyama N, Iwata M, Nagai T. Pharmaceutical interactions in dosage forms and processing- Part XVII: Preparation and phase II clinical examination of topical dosage forms for the treatment of carcinoma colli containing bleomycin, carboquone or 5-flourouracil with hydroxypropyl cellulose and carbopol®. *Chem Pharm Bull* 1980; 28(4): 125-30.
78. Ruiz MA, Gallardo V, Delgado A, Vera P. Study of in vitro release of corticoids in topicals formulations. *J Pharmaco* 1994; 49(2): 147-52.
79. Sanghavi NM, Puri RD, Kamath PR. Study on topical piroxicam formulations. *Ind Drugs* 1989; 26(4): 165-68.
80. Strauss JS, Goldman PH, Nacht S, Gans EH. A reexamination of the potential comedogenicity of sulphur. *Arch Dermatol* 1978; 114.
81. Reynolds JEF. *Martindale: The extra pharmacopoeia*. 30<sup>th</sup> ed. London: Pharmaceutical Press; 1993. p.903.
82. Poulsen BJ, Young E, Coquiolla V, Katz M. The effect of topical vehicle composition on the in vitro release of flucinolone acetonide and its acetate ester. *J Pharm Sci* 1968; 57: 928-33.
83. Arellano A, Santoyo S, Martin C, Ygartua P. Influence of propylene glycol and isopropyl myristate on the *in vitro* percutaneous penetration of diclofenac sodium from Carbopol® gels. *Eur J Pharm Sci* 1998; 7: 129-35.
84. Patel MM, Sheth MN, Hariyanawala AI. Studies in the transdermal formulations of metoprolol tartrate and their evaluation using human cadaver skin. *The Eastern Pharmacist* 1993; 129-31.
-



- 
85. Patel RP, Patel GI, Kamani R. Formulation, optimization and evaluation of Mometasone furoate gel. *J Pharm Res* 2009; 2(11): 1720-24.
86. Gondaliya DP, Pundarikakshudu K. Studies on preparation, characterization and transdermal permeation of nimesulide from aqueous and emulgel. *Ind Drugs* 2002; 39(9): 465-73.
87. Sanghavi NM, Puri RD, Kamath PR. Study of topical piroxicam formulations. *Ind Drugs* 1988; 26(4): 1-4.
88. Patel MM, Sheth MN, Hariyanawala AI. Comparative studies in the release profile of Metoprolol tartrate from transdermal gel using human and animal skins. *The Eastern Pharmacist* 1995; 137-38.
89. Arul B, Sathyamurthy D. Formulation and evaluation of Ketorolac tromethamine gels. *The Eastern Pharmacist* 1998; 135-36.
90. Amin PD, Tayade PT, Dhavse VV. Evaluation of Ketorolac tromethamine gels for ocular anti-inflammatory activity in rabbits. *The Eastern Pharmacist* 1998; 127-30.
91. Gaud RS, Gupta GD. Release rate of Nimesulide from different gellants. *Ind J Pharm Sci* 1999; 61(4): 227-30.
92. Chowdary KPR, Kumar PA. Formulation and evaluation of topical drug delivery systems of Ciprofloxacin. *Ind J Pharm Sci* 1996; 58(2): 47-50.
93. Isobel A, Stanley SD. The formulation and sterilization of a surgical lubricant gel based on carboxypolymethylene. *J Pharm Pharmacol* 1973; 25: 640-46.
94. James N, Victor M. Benzoyl peroxide stability in pharmaceutical gel preparation. *J Pharm Sci* 1977; 66: 718.
95. Mayer MC, Barry BW. The rheological properties of carbopol gels-1: Continuous shear and creep properties of carbopol gels. *Int J Pharm* 1979; 2: 1-2.


96. Khalil-Al-Khamis., Stainley SD, Hadgraft J. In vitro-in vivo correlations for the percutaneous absorption of Salicylates. *Int J Pharm* 1987; 40: 111-18.
97. Chiang CM, Flynn GL, Weiner ND, Addicks WJ, Szpunar GJ. Bioavailability assessment of topical delivery systems: in vitro delivery of minoxidil from prototypical semi solid formulations. *Int J Pharm Sci* 1989; 49:109-14.
98. Udupa N, Jaynathi C. In-vitro and in-vivo studies of norfloxacin gels. *The Eastern Pharmacist* 1993; 131-34.
99. Chowdary KPR, Naidu RAS. Design of transdermal drug delivery systems: Effect of semisolid formulations on transdermal diffusion of diclofenac sodium. *Ind Drugs* 1994; 31: 36-40.
100. Gupta GD, Gaud RS. Anti inflammatory activity of tenoxicam gel on carageenan induced paw edema in rats. *Ind J Pharm Sci* 2006; 356-59.
101. Chowdary KPR, Appan Kumar P. Release and antimicrobial activity of ciprofloxacin from topical drug delivery systems. *The Eastern Pharmacist* 1995; 145-46.
102. Loganathan V, Rajasekaran R. The effect of polymers and permeation enhancers on releases of flurbiprofen from gel formulation. *Ind J Pharm Sci* 2001; 63(3): 200-04.
103. Patel RP, Kamani R. Formulation, optimization and evaluation of Mometasone furoate cream. *J Pharm Res* 2009; 2(10):1565-69.
104. Anil Kumar SJ, Bhise SB, Jarag RJ, Jadhav NR. Preparation of cream containing Tridax Procumbens, Curcuma Longa and Azadirachta Indica and its evaluation for wound healing property. *Ind Pharma* 2005; 41:107-10.
105. Morteza, SK, Saeedib M, Hamidiana M. Anti-inflammatory and analgesic activity of the topical preparation of Glaucium grandiflorum. *Fitoterapia* 2004; 75: 123-29.

106. Feresin GE, Tapia A, Sortino MZ, Antonieta RA, Inchausti A. Bioactive alkyl phenols and embelin from *Oxalis erythrorhiza*. *J Ethnopharmacol* 2003; 88: 241-47.
107. Rao D, Pulla rao J, Ramana rao VV. Antifungal, antibacterial and anthelmintic activities of different isolated derivatives of embelin. *Ind J Chem* 1983; 833-39.
108. Chitra CS, Shyamala devi CS, Sukumar E. Antibacterial activity of embelin. *Fitoterapia* 2003; 74(4): 401-03.
109. Namba T, Tsunozuka M, Dissanayake D. Studies on dental caries prevention by traditional medicines (Part-VII), Screening of Ayurvedic medicine for anti-plaque action. *Shoyakugaku Zasshi* 1985; 39(2): 146-53.
110. Kumara Swamy HM, Krishna V, Shankarmurthy K, Rahiman BA, Mankani KL, Mahadevan KM. et.al. Wound healing activity of embelin isolated from the ethanol extract of leaves of *Embelia ribes* Burm. *J Ethnopharmacol* 2007; 109: 529-34.
111. Sarin JPS, Ray GK. Colorimetric method development for the estimation of embelin in *Embelia ribes*. *Ind J Pharm* 1961; 23(12): 330-31.
112. Patel RB, Patel MR, Pandya SS, Pundarikakshudu K, Banerjee S. Colorimetric determination of embelin in *Embelia ribes*. *Ind Drugs* 1997; 34(10): 590-92.
113. Rao B, Venkateswarlu V. Method development for gravimetric determination of embelin as vilangin in *Embelia ribes*. *Ind J Pharm* 1962; 24(10): 252.
114. Chauhan SK, Singh B. Determination of embelin from *Embelia ribes* by high performance thin layer chromatography. *Ind Drugs* 1999; 36(10): 41-3.
115. Rao VD, Ramana rao VV, Pulla rao J, Subramaniam B. Anthelmintic activity of embelin. *Ind J Pharm Sci* 1986; 2: 37.


- 
116. Patel RK, Pundarikakshudu K, Momin M, Patel MM. Studies on formulation and *in vitro* dissolution of Embelin tablets. *Ind J Pharma Sci* 2006; 68(2): 227-30.
117. Chitra M, Sukumar E, Suja V, Shyamala Devi CS. Antitumour, anti inflammatory and analgesic property of embelin, a plant product. *Chemother* 1994; 40:109-13.
118. Qadry JS. *Pharmacognosy*. 13<sup>th</sup> ed. Ahmedabad: B.S.Shah Prakashan; 2008. p. 178-79.
119. *Indian Herbal Pharmacopoeia*. Revised new ed. Mumbai: Indian drug manufacturers association; 2002. App. II, p. 493.
120. Kokate CK. *Practical pharmacognosy*. 4<sup>th</sup> ed. Delhi: Vallabh prakashan; 2005. p. 79.
121. Ali M. *Text book of pharmacognosy*. 2<sup>nd</sup> ed. New Delhi: CBS Publishers & Distributors pvt. Ltd.; 2009. p. 390.
122. Bolton S. *In: Pharmaceutical statistics*, 3<sup>rd</sup> ed. New York: Marcel dekker, Inc; 1997. p. 326.
123. Mohamed MI. Optimization of chlorphenesin emulgel formulation. *The AAPS Journal* 2004; 6 (3): 1-7.
124. Patel RP, Patel HK, Baria AH. Formulation and evaluation of carbopol gel containing liposomes of ketoconazole. *Int J Drug Delivery Tech* 2009; 1(2): 42-45.
125. Stability studies in overview of ICH guidelines for drug products: Natalie Mc Clure, Matrix Pharmaceutical Inc; 1997 <http://www.mcclurenet.com>.
126. Sidney HW, James RS. *Good Manufacturing Practices for Pharmaceuticals: A Plan for Total Quality Control*. Stability testing. 4<sup>th</sup> ed. Revised and Expanded. p. 147-51.

- 
127. Guidance for Industry: SUPAC-SS Nonsterile Semisolid Dosage Forms. Scale-Up and Post approval Changes: Chemistry, Manufacturing, and Controls. *In Vitro* Release Testing and *In Vivo* Bioequivalence Documentation. US Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research. May 1997.
  128. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS Guidelines to dissolution/*in vitro* release testing of novel/special dosage forms.. *AAPS Pharm Sci Tech* 2003; 2: 1-10.
  129. Reppas C, Nicolaidis E. *Analysis of drug dissolution data*. In: Dressman, JB, Lennernas H. Oral Drug Absorption Prediction and Assessment. New York: Marcel Dekker; 2000. p. 229-54.
  130. Vueba ML, Batista de Carvalho LAE, Veiga F, Sousa JJ, Pina ME. Influence of cellulose ether polymers on ketoprofen release from hydrophilic matrix tablets. *Eur J Pharm Biopharm* 2004; 58: 51-59.
  131. Moore JW, Flanner H. Mathematical comparison of dissolution profiles. *Pharma Tech* 1996; 20(6): 64-74.

## CERTIFICATE OF HERBARIUM



**निस्केयर**  
**NISCAIR**



**राष्ट्रीय विज्ञान संचार एवं सूचना स्रोत संस्थान**  
**NATIONAL INSTITUTE OF SCIENCE COMMUNICATION**  
**AND INFORMATION RESOURCES**  
(वैज्ञानिक एवं औद्योगिक अनुसंधान परिषद्)  
(Council of Scientific and Industrial Research)  
14, सत्संग विहार मार्ग, नई दिल्ली 110 067  
14, SATSANG VIHAR MARG, NEW DELHI 110 067 &  
डा. के. एस. कृष्णन् मार्ग, नई दिल्ली - 110 012  
Dr. K. S. KRISHNAN MARG (Near Pusa Gate), NEW DELHI 110 012

Ref. NISCAIR/RHMD/Consult/-2009-10/1251/55 13 August 2009

**Dr. H.B. Singh**  
Scientist F & Head  
Raw Materials Herbarium & Museum  
Phone: 011-25841143  
E-mail: [hbs@niscair.res.in](mailto:hbs@niscair.res.in); [hbsbhati@yahoo.com](mailto:hbsbhati@yahoo.com)


Dear Mr. Patel

Kindly refer to your letter No. VIP/RES/DVP/ER/01 dated 08.08.2009 regarding identification of one crude drug sample. The sample has been identified as given below:

Sl No	Sample Received as	Part	Sample Identified as	Remarks
01	Embelia ribes	Seeds	Embelia ribes (R. & S.) A.DC.	OK

With regards Yours sincerely

**Mr. Patel Dhavalkumar V.**  
C/o Mr. Ojas mahendrabhai Soni  
Sankdi Sheri, Soni Bazar  
Mandvi-370465,  
Bhuj (Kachchh), Gujarat

  
(Dr. H.B. Singh)

---

दूरभाष/Phone: सत्संग विहार मार्ग/Satsang Vihar Marg: 91-11-26560141, 26560143, 26560165 फैक्स/Fax: 91-11-26862228  
 दूरभाष/Phone: डा. के. एस. कृष्णन् मार्ग/Dr. K. S. Krishnan Marg: 91-11-25846301, 25842303, 25846304-07, 25842990, 25840602, 25865131-32 फैक्स/Fax: 91-11-25847062, 25849949  
 ई-मेल/E-mail: [coa@niscair.res.in](mailto:coa@niscair.res.in) [naresh@niscair.res.in](mailto:naresh@niscair.res.in) वेबसाइट/Website: [www.niscair.res.in](http://www.niscair.res.in)